Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Clindamycin Palmitate Hydrochloride (pediatric)
Brand Name
Clindamycin Palmitate Hydrochloride (pediatric)
Generic Name
Clindamycin Palmitate Hydrochloride (pediatric)
Active Ingredient
Clindamycin PalmitateCategory
Other
Salt Form
Hydrochloride
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Clindamycin Palmitate Hydrochloride (pediatric), you must consult a qualified healthcare professional.
Detailed information about Clindamycin Palmitate Hydrochloride (pediatric)
Clindamycin Palmitate is a lincosamide antibiotic prodrug used primarily in pediatric and adult patients to treat serious bacterial infections caused by susceptible anaerobic and Gram-positive aerobic organisms.
While Clindamycin Palmitate (the liquid form) is frequently associated with pediatric use, it is also prescribed for adults who cannot swallow capsules. For serious infections in adults, the standard dosage typically ranges from 150 mg to 300 mg every 6 hours. For more severe or life-threatening infections, the dosage may be increased to 300 mg to 450 mg every 6 hours. The total daily dose is usually divided into four equal administrations to maintain consistent therapeutic levels in the bloodstream. Healthcare providers determine the exact dose based on the severity of the infection and the patient's overall health status.
Dosage for children is strictly calculated based on total body weight to ensure safety and efficacy. The FDA-approved range for pediatric patients is 8 to 25 mg/kg/day, divided into three or four equal doses.
In children weighing 10 kg or less, the minimum recommended dose is 37.5 mg (2.5 mL of the 75mg/5mL solution) three times a day. It is critical that parents use a calibrated measuring device (oral syringe or dose cup) rather than a household teaspoon to ensure accuracy.
In patients with mild to moderate renal (kidney) disease, dose adjustments are generally not required because the liver is the primary site of metabolism. However, in cases of severe renal impairment, healthcare providers may monitor serum clindamycin levels or adjust the frequency of dosing to prevent accumulation of the drug.
Since clindamycin is primarily metabolized by the liver, patients with moderate to severe hepatic (liver) disease may experience a significantly prolonged half-life. While specific dose reduction formulas are not standardized, doctors will typically monitor liver function tests and may reduce the total daily dose or extend the interval between doses.
Clinical studies have shown that the risk of developing severe diarrhea and Clostridioides difficile-associated diarrhea (CDAD) is higher in patients over the age of 60. Therefore, elderly patients should be monitored closely for changes in bowel frequency. No specific age-based dose reduction is mandated, but the "start low and go slow" approach is often prudent.
If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not "double up" or take two doses at once to make up for a missed one, as this increases the risk of side effects.
Symptoms of an overdose are generally similar to the drug's side effects but may be more intense, including severe abdominal pain, nausea, vomiting, and diarrhea. In the event of a suspected overdose, contact your local Poison Control Center or seek emergency medical attention immediately. There is no specific antidote for clindamycin; treatment is supportive and focused on maintaining hydration and managing symptoms.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication without medical guidance, as this can impact the effectiveness of the treatment.
Side effects involving the gastrointestinal tract are the most frequently reported issues with Clindamycin Palmitate. Because the drug can alter the normal bacterial flora of the gut, many patients experience:
Clindamycin Palmitate is a potent antibiotic that must be used with caution. It is not intended for minor infections, such as the common cold or flu, as it does not treat viral infections. Misuse of the drug can lead to decreased effectiveness and the development of drug-resistant bacteria. Patients must be aware that the most significant risk associated with this medication is its impact on the gastrointestinal system, specifically the risk of life-threatening colitis.
Full FDA Text Summary: Clindamycin can cause Clostridioides difficile-associated diarrhea (CDAD), which ranges in severity from mild diarrhea to fatal colitis. Because of the risk of CDAD, which can occur during or even weeks after the completion of therapy, clindamycin should be reserved for serious infections where other antibiotics are not suitable. If significant diarrhea occurs, the drug should be discontinued immediately, and the patient should be evaluated for CDAD. This condition is caused by the overgrowth of C. difficile bacteria, which produce toxins that damage the lining of the colon.
Erythromycin: Clindamycin and erythromycin should not be used together. Both antibiotics bind to the same site (the 50S subunit) on the bacterial ribosome. When used simultaneously, they compete for this binding site, which can lead to antagonism—meaning they may cancel each other out and reduce the effectiveness of both drugs.
Neuromuscular Blocking Agents: Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents (such as succinylcholine, vecuronium, or pancuronium). This is particularly important for patients undergoing surgery. If you are scheduled for a procedure involving anesthesia, ensure the anesthesiologist knows you are taking Clindamycin Palmitate, as it could lead to prolonged muscle relaxation or respiratory depression.
CYP3A4 Inducers (e.g., Rifampin)
There are specific clinical scenarios where Clindamycin Palmitate must NEVER be used due to the risk of life-threatening complications:
FDA Pregnancy Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women. Clindamycin does cross the placenta. Clinical data from the use of clindamycin during the second and third trimesters have not shown an increased frequency of congenital abnormalities. However, Clindamycin Palmitate should be used during pregnancy only if clearly needed and prescribed by a healthcare provider. It is generally avoided in the first trimester unless the infection is life-threatening and no safer alternative exists.
Clindamycin has been reported to appear in human breast milk in ranges from 0.7 to 3.8 mcg/mL. While it is generally considered compatible with breastfeeding by some authorities, there is a risk that the drug may affect the infant's gastrointestinal flora. This could lead to diarrhea, thrush (candidiasis), or, in rare cases, blood in the stool. Nursing mothers should monitor their infants closely for these symptoms. In some cases, a doctor may recommend temporarily pumping and discarding milk or switching to formula during the treatment period.
Clindamycin Palmitate is a prodrug that is hydrolyzed in the body to its active form, clindamycin. The molecular mechanism involves the inhibition of bacterial protein synthesis. Specifically, clindamycin binds to the 23S RNA of the 50S subunit of the bacterial ribosome. This binding site overlaps with those of the macrolides (like erythromycin) and chloramphenicol. By binding here, clindamycin blocks the transpeptidation and translocation steps of protein synthesis, preventing the elongation of the polypeptide chain. This effectively stops the bacteria from producing the essential proteins required for survival and replication.
The efficacy of clindamycin is primarily related to the time that the serum concentration of the drug remains above the Minimum Inhibitory Concentration (MIC) for the infecting organism (Time > MIC). It exhibits a post-antibiotic effect (PAE), meaning it continues to suppress bacterial growth for a period even after the drug levels drop below the MIC. Resistance to clindamycin can occur via several mechanisms, most notably the methylation of the ribosomal binding site (often encoded by erm genes), which can lead to cross-resistance with macrolides and streptogramins (MLSB resistance).
Common questions about Clindamycin Palmitate Hydrochloride (pediatric)
Clindamycin Palmitate is primarily used to treat serious bacterial infections caused by susceptible organisms, such as certain types of staph and strep. It is frequently prescribed for skin and soft tissue infections, respiratory tract infections like pneumonia, and internal infections of the abdomen or female reproductive system. Because it is a potent antibiotic with a risk of serious gastrointestinal side effects, it is often reserved for patients who cannot take penicillins or when other antibiotics have failed. The palmitate form is specifically a liquid version often used for children or adults who cannot swallow pills. Your doctor will determine if your specific infection is sensitive to this medication before prescribing it.
The most common side effects of Clindamycin Palmitate involve the digestive system, including nausea, vomiting, stomach pain, and mild diarrhea. Some patients also report a metallic or bitter taste in the mouth after taking the liquid solution. Skin rashes are another relatively common occurrence and should be monitored. While many of these symptoms are manageable, any diarrhea that becomes severe, watery, or bloody must be reported to a doctor immediately. This is because clindamycin can cause a serious condition called C. diff-associated diarrhea. Always keep your healthcare provider informed of any new or worsening symptoms during your treatment.
There is no known direct chemical interaction between alcohol and Clindamycin Palmitate that causes a dangerous reaction like the one seen with metronidazole. However, healthcare providers generally recommend avoiding alcohol while taking antibiotics. Alcohol can cause dehydration and irritate the stomach lining, which may worsen the common gastrointestinal side effects of clindamycin, such as nausea or diarrhea. Furthermore, alcohol can suppress the immune system and interfere with the body's ability to recover from a serious infection. For the best recovery results, it is wise to abstain from alcohol until you have finished your course of antibiotics and feel fully recovered.
Clindamycin Palmitate is classified as FDA Pregnancy Category B, which means animal studies haven't shown a risk to the fetus, but there aren't enough high-quality studies in pregnant humans to be certain. It is known to cross the placenta and reach the baby's circulation. Clinical data from the second and third trimesters have generally not shown an increased risk of birth defects. However, it should only be used during pregnancy if your doctor decides the benefit to the mother outweighs the potential risk to the fetus. If you are pregnant or planning to become pregnant, you must discuss the necessity of this antibiotic with your obstetrician or healthcare provider.
Most patients begin to feel an improvement in their symptoms within 24 to 48 hours of starting Clindamycin Palmitate. However, the exact time depends on the severity and location of the infection. Even if you feel significantly better after just a few doses, it is critical to continue taking the medication for the full duration prescribed by your doctor. Stopping the antibiotic too early can allow the remaining bacteria to multiply, leading to a relapse of the infection. If you do not notice any improvement in your symptoms after three days of treatment, you should contact your healthcare provider to re-evaluate the diagnosis.
You should not stop taking Clindamycin Palmitate suddenly unless you are experiencing a severe allergic reaction or significant diarrhea. If you stop the medication before the full course is completed, the infection may not be fully cleared, and the surviving bacteria could develop resistance to the antibiotic. This makes future infections much harder to treat. However, if you develop watery or bloody diarrhea, you should stop the medication immediately and call your doctor, as this is a sign of a potentially life-threatening colon infection. Always consult with your medical professional before making any changes to how you take your prescribed medication.
If you miss a dose of Clindamycin Palmitate, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and simply take the next one at the regular time. You should never take two doses at once to make up for a missed one, as this can increase the risk of stomach upset and other side effects. To help prevent missing doses, try taking the medication at the same times every day, such as with breakfast and dinner. If you find yourself frequently forgetting doses, talk to your pharmacist about using a reminder app or a pill-tracking chart.
Weight gain is not a recognized or common side effect of Clindamycin Palmitate. In fact, because the drug frequently causes gastrointestinal issues like nausea, loss of appetite, or diarrhea, some patients might actually experience temporary weight loss during treatment. If you notice significant or rapid weight gain while taking this medication, it is likely due to another factor, such as fluid retention or a different underlying condition. You should report any unusual swelling or rapid weight changes to your doctor, as these could be signs of kidney or heart issues. Always discuss concerns about weight and medication side effects with your clinical team.
Clindamycin Palmitate can interact with several other medications, so it is vital to provide your doctor with a full list of everything you are taking. It should not be taken with erythromycin, as the two drugs can block each other's effectiveness. It may also increase the effects of neuromuscular blocking agents used during surgery, which can be dangerous. Some medications like rifampin may lower the levels of clindamycin in your blood, making it less effective. Always check with your pharmacist before starting any new over-the-counter drugs or supplements while on this antibiotic. Probiotics may be taken but should be spaced at least two hours apart from your dose.
Yes, Clindamycin Palmitate Hydrochloride is available as a generic medication. The brand-name version is often known as Cleocin Pediatric. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove bioequivalence, meaning they work the same way in the body. Choosing the generic version can often be more cost-effective for patients and is widely available at most pharmacies. If you have questions about the cost or availability of the generic versus the brand name, your pharmacist is the best resource for that information.
Other drugs with the same active ingredient (Clindamycin Palmitate)
> Warning: Stop taking Clindamycin Palmitate and call your doctor immediately if you experience any of the following serious symptoms:
Prolonged use of Clindamycin Palmitate can lead to the overgrowth of non-susceptible organisms, particularly fungi and yeast. This may result in oral thrush (white patches in the mouth) or persistent vaginal yeast infections. Long-term use also increases the cumulative risk of developing CDAD. Routine blood work, including liver and kidney function tests, is usually recommended if the drug is used for an extended period (beyond 10–14 days).
Clindamycin Palmitate carries a significant FDA Black Box Warning regarding its potential to cause severe colitis (inflammation of the colon).
Summary of Warning: Clindamycin therapy has been associated with severe colitis which may end fatally. It should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. Because clindamycin therapy has been associated with severe colitis, it is essential to monitor patients closely for diarrhea and to discontinue the drug if significant diarrhea occurs.
Report any unusual symptoms or changes in bowel habits to your healthcare provider immediately to ensure safety during your course of treatment.
Severe hypersensitivity reactions, including anaphylaxis (a life-threatening allergic reaction), have been reported. Patients with a known allergy to clindamycin or lincomycin must not take this medication. If you experience hives, swelling, or difficulty breathing, seek emergency care immediately.
Clindamycin Palmitate should be prescribed with extreme caution to individuals with a history of gastrointestinal disease, particularly colitis, Crohn's disease, or ulcerative colitis. The drug's tendency to alter gut flora can exacerbate these underlying conditions.
While rare, clindamycin has been associated with liver injury. Patients with pre-existing liver disease should be monitored closely. Signs of liver trouble include persistent nausea, yellowing eyes/skin, and dark urine.
Serious skin reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported. These are medical emergencies that often start with flu-like symptoms followed by a painful rash that spreads and blisters.
If you are on Clindamycin Palmitate for a prolonged period, your healthcare provider will likely order periodic laboratory tests to monitor your health:
Clindamycin Palmitate generally does not interfere with the ability to drive or operate heavy machinery. However, if you experience rare side effects like dizziness or severe malaise, you should avoid these activities until you feel stable.
There is no direct chemical interaction between alcohol and Clindamycin Palmitate that causes a "disulfiram-like" reaction (unlike metronidazole). However, alcohol can irritate the gastrointestinal tract and dehydrate the body, which may worsen the GI side effects of the antibiotic. It is generally recommended to avoid alcohol while fighting a serious infection to support the immune system.
Unlike some psychiatric or blood pressure medications, Clindamycin Palmitate does not require a tapering schedule. However, it is vital to complete the full course prescribed. Discontinuing the drug early because symptoms have improved can lead to a relapse of the infection with bacteria that are now resistant to clindamycin.
> Important: Discuss all your medical conditions, especially any history of bowel disease or allergies, with your healthcare provider before starting Clindamycin Palmitate.
CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole): These drugs can inhibit the metabolism of clindamycin, leading to increased levels in the blood and a higher risk of side effects. While generally manageable, monitoring for increased toxicity is recommended.
Clindamycin Palmitate is unique among many antibiotics because its absorption is not significantly affected by food. It can be taken with meals or on an empty stomach. Taking it with a full glass of water or food may actually help reduce the risk of stomach upset or esophageal irritation. There are no known interactions with grapefruit juice or dairy products that would require restriction.
Clindamycin Palmitate does not typically interfere with common laboratory tests, such as glucose or electrolyte panels. However, it may cause transient elevations in liver enzymes (AST, ALT, and bilirubin) on a liver function panel. Always inform the laboratory staff and your physician of all medications you are taking before blood work is performed.
Management Strategy: For most interactions, the primary strategy is clinical monitoring. If an interaction is suspected to be reducing efficacy, the doctor may choose an alternative antibiotic. If an interaction increases toxicity risk, the dose may be adjusted or the frequency of monitoring for side effects (like diarrhea) may be increased.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs, to prevent dangerous interactions.
These are conditions where the drug should be used only if the benefits clearly outweigh the risks, and under strict medical supervision:
Patients should be aware of cross-sensitivity with the lincosamide class. If you are allergic to lincomycin, you are considered allergic to clindamycin. There is no known cross-sensitivity between clindamycin and penicillins or cephalosporins, making clindamycin a common alternative for patients with those specific allergies. However, always confirm your allergy history with your specialist.
> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to antibiotics and any chronic bowel issues, before prescribing Clindamycin Palmitate to ensure it is the safest choice for you.
Clinical experience has shown that elderly patients (60 years and older) may tolerate the side effects of clindamycin less well than younger patients. Specifically, they are at a higher risk for severe diarrhea and pseudomembranous colitis. When treating elderly patients, doctors will often monitor bowel frequency more closely. There are no significant differences in the effectiveness of the drug in older versus younger adults, but age-related declines in liver or kidney function may necessitate closer observation for toxicity.
In patients with renal impairment, the half-life of clindamycin is slightly prolonged, but not usually to a degree that requires a dose reduction for mild to moderate cases. Clindamycin is not significantly removed by hemodialysis or peritoneal dialysis; therefore, no supplemental doses are needed after a dialysis session. In cases of end-stage renal disease, monitoring of serum drug levels may be considered.
Because the liver is the primary organ for clindamycin metabolism, patients with significant hepatic impairment (e.g., cirrhosis) will experience higher and more prolonged serum levels of the drug. For patients with severe liver disease, the dosage should be adjusted, or the dosing interval should be increased. Liver function tests (ALT, AST, Bilirubin) should be performed regularly during treatment in this population.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding before starting this medication.
| Parameter | Value |
|---|---|
| Bioavailability | ~90% (Rapidly absorbed) |
| Protein Binding | 60% - 94% (Primarily to alpha-1-acid glycoprotein) |
| Half-life | 2.4 - 3.2 hours (Adults); ~2 hours (Children) |
| Tmax | 45 - 60 minutes |
| Metabolism | Hepatic (CYP3A4, CYP3A5) |
| Excretion | Renal (~10%), Fecal (~4%), Remainder as metabolites |
Clindamycin Palmitate is classified as a Lincosamide Antibiotic. It is the only widely used member of this class in modern clinical practice in the United States, following the decreased use of its parent compound, lincomycin. It is often grouped with macrolides and tetracyclines in educational contexts because they all inhibit protein synthesis, but its unique chemical structure and specific binding site make it a distinct therapeutic option.